How Much Does AndroGel Cost in Oklahoma in 2026?

Oklahoma Retail Cash Price for AndroGel

The average cash price for a 30-day supply of brand-name AndroGel 1.62% across Oklahoma retail pharmacies sits at approximately $510. That figure tracks closely with AbbVie's manufacturer list price and has held steady through early 2026. Prices vary modestly between metro-area chains in Oklahoma City and Tulsa versus independent rural pharmacies, but the spread is typically less than $30 in either direction.

AndroGel received FDA approval for testosterone replacement in adult males with conditions associated with a deficiency or absence of endogenous testosterone. The branded product uses a hydroalcoholic gel base that delivers testosterone transdermally, producing steady-state serum levels within approximately 24 hours of the first application. Because no AB-rated generic exists for the 1.62% formulation, pharmacies cannot automatically substitute a less expensive equivalent at the counter. This single factor keeps Oklahoma cash prices anchored near the list price.

For patients paying out of pocket, GoodRx and RxSaver coupons sometimes bring the effective cost down to the $380 to $440 range at select Oklahoma locations, though availability shifts month to month. Confirm the coupon price at checkout; the quoted discount is not guaranteed.

Oklahoma Medicaid and AndroGel Coverage

Oklahoma Medicaid does not cover AndroGel. The state's preferred drug list excludes branded testosterone gels entirely. Patients enrolled in SoonerCare who need testosterone replacement therapy face an out-of-pocket barrier unless their provider can document medical necessity for an exception, and approvals are rare.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism confirmed by at least two morning serum testosterone measurements below the lower limit of normal. Despite this guideline, state Medicaid formularies vary widely in what they will reimburse. Oklahoma's exclusion means that Medicaid patients often end up on intramuscular testosterone cypionate, which is covered and costs approximately $30 to $50 per month at most Oklahoma pharmacies.

Patients who strongly prefer a gel formulation should ask their prescriber about a compounded testosterone gel (covered in the next section) or explore whether they qualify for the AbbVie patient assistance program, which provides brand AndroGel at no cost to uninsured patients below specific income thresholds.

Compounded Testosterone Gel: Oklahoma's $120 Alternative

Compounded testosterone gel from a licensed 503A pharmacy is legal in Oklahoma and typically costs around $120 per month. These pharmacies operate under state Board of Pharmacy oversight and compound individual prescriptions based on a practitioner's order.

The distinction matters clinically. The FDA's guidance on 503A compounding requires these pharmacies to prepare medications in response to individual patient prescriptions, use ingredients meeting USP-grade standards, and refrain from essentially copying a commercially available product without a clinical change. A prescriber can order a compounded testosterone gel at a different concentration (for example, 5% or 10%) or in a different base than AndroGel's hydroalcoholic formulation. That clinical modification satisfies the regulatory standard.

Oklahoma has multiple 503A pharmacies across the Oklahoma City, Tulsa, and Norman metro areas. Some compound topical testosterone in cream form rather than gel. Creams use a different vehicle and may absorb differently. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies in 790 men aged 65 and older, demonstrated that raising testosterone to the mid-normal range for younger men improved sexual function, physical activity, and mood. Those trials used AndroGel 1%, but the principle of achieving target serum levels applies regardless of whether the vehicle is a branded gel or compounded formulation, provided the pharmacy compounds to USP standards.

Patients using compounded testosterone should have follow-up labs drawn at 3 months and then every 6 to 12 months, consistent with Endocrine Society monitoring recommendations, to confirm that serum testosterone reaches the 400 to 700 ng/dL target range.

Insurance Coverage for AndroGel in Oklahoma

Most large commercial insurers operating in Oklahoma (Blue Cross Blue Shield of Oklahoma, UnitedHealthcare, Aetna, Cigna) place AndroGel on a non-preferred brand tier, which means higher copays and mandatory prior authorization. The typical out-of-pocket copay for a Tier 3 branded drug in Oklahoma commercial plans runs $60 to $120 per month after prior authorization is approved.

Prior authorization usually requires documentation of two early-morning serum total testosterone levels below 300 ng/dL, recorded on separate days, plus signs and symptoms consistent with hypogonadism. These criteria mirror the AUA/Endocrine Society diagnostic threshold. Some plans also require a trial of injectable testosterone cypionate before approving gel coverage, a step-therapy requirement that adds 60 to 90 days before the patient can access AndroGel.

Oklahoma's state employee health plan (HealthChoice) follows a similar prior authorization process. Veterans enrolled in the VA system may access testosterone gel through the VA formulary, though the VA often prefers generic testosterone 1% gel packets over brand AndroGel 1.62%.

A 2020 analysis of commercial claims data found that mean annual spending on branded testosterone gels exceeded $4,800 per patient, underscoring why insurers gate access behind prior authorization.

The AbbVie Savings Card in Oklahoma

AbbVie offers a manufacturer copay savings card for AndroGel that can reduce the patient's monthly copay to as low as $0 for commercially insured patients. The card has a maximum annual benefit (typically $3,600 to $4,800 per year, depending on the current program terms), after which the patient reverts to their plan's standard copay.

Key eligibility rules: the patient must have commercial insurance that covers AndroGel (even at a high copay tier), must not be enrolled in any government-funded program (Medicare, Medicaid, Tricare, VA), and must be a resident of the United States. Oklahoma patients meeting these criteria can activate the card online or through their prescriber's office.

The savings card does not apply to the full cash price. A patient with no insurance coverage at all cannot use the card to turn a $510 monthly bill into $0. For uninsured Oklahoma patients, the AbbVie patient assistance program is the alternative, providing free medication to qualifying low-income individuals.

Patients should also check whether their plan counts the manufacturer's copay contribution toward the annual deductible. Under Oklahoma-regulated fully insured plans, accumulator adjustment programs may prevent copay card amounts from counting toward out-of-pocket maximums, which can create an unexpected cost cliff mid-year.

Telehealth Prescribing of AndroGel in Oklahoma

Oklahoma permits telehealth prescribing of testosterone gel. A provider licensed in Oklahoma can evaluate a patient via synchronous video visit, review qualifying labs, and transmit a prescription for AndroGel or compounded testosterone gel to an Oklahoma pharmacy. No in-person visit is required for the initial prescription under current Oklahoma telehealth regulations.

Telehealth testosterone clinics have expanded access for patients in rural western Oklahoma, where endocrinology specialists are sparse. A 2021 study in the Journal of the Endocrine Society found that telemedicine-managed testosterone replacement achieved equivalent serum testosterone normalization rates compared to in-person management, with no significant difference in adverse events over 12 months.

Patients using telehealth should ensure the provider orders a comprehensive baseline lab panel before initiating therapy. The Endocrine Society guideline recommends baseline measurement of total testosterone (two separate morning draws), PSA, hematocrit, lipid panel, and liver function tests. Follow-up hematocrit checks at 3 to 6 months are especially important, since testosterone therapy increases erythropoiesis and can raise hematocrit above 54%, a threshold associated with increased thromboembolic risk.

Some telehealth platforms operating in Oklahoma offer bundled pricing that includes the consultation, lab orders, and a 90-day supply of compounded testosterone gel for $150 to $250 per quarter, making them cost-competitive with the $120/month standalone compounded gel price.

AndroGel vs. Injectable Testosterone: Cost Comparison in Oklahoma

Injectable testosterone cypionate is the cheapest prescription testosterone option in Oklahoma. A 10 mL vial of 200 mg/mL testosterone cypionate costs $30 to $50 at most pharmacies and lasts 10 to 20 weeks depending on dose. That works out to roughly $10 to $20 per month.

The tradeoff is pharmacokinetic. Injections produce peak-and-trough cycling, with supraphysiologic levels in the first 24 to 48 hours followed by a decline toward the lower end of normal by the end of the injection interval. Daily topical gel application mimics the body's natural circadian testosterone pattern more closely, producing steadier serum levels. Some patients report fewer mood swings, less acne, and more consistent energy on gel versus injections, though head-to-head trial data comparing patient-reported outcomes are limited.

A secondary analysis from the Testosterone Trials showed that the gel formulation improved depressive symptoms as measured by the PHQ-9 in men with hypogonadism and baseline low-grade depression. The sexual function improvements were also significant: libido, erectile function, and sexual activity all increased relative to placebo over the 12-month study period.

For Oklahoma patients whose primary concern is cost and who are comfortable with self-injection, testosterone cypionate remains the most economical choice. For those who prefer a non-injectable daily option, compounded testosterone gel at $120/month offers the best value. Brand AndroGel at $510/month is the premium option, justified mainly by its standardized metered-pump delivery and extensive safety data from the original registration trials.

Safety Monitoring on Testosterone Gel in Oklahoma

Any man starting testosterone gel in Oklahoma, whether brand or compounded, needs structured follow-up. The Endocrine Society's 2018 guideline specifies monitoring at 3 months, 6 months, and then annually. Required labs include serum testosterone (drawn 2 to 8 hours after gel application), hematocrit, PSA, and a metabolic panel.

Polycythemia is the most common lab abnormality. The TRAVERSE trial (N=5,246), a cardiovascular safety study of transdermal testosterone in men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease, found that testosterone gel did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo over a mean follow-up of 33 months. The hazard ratio for MACE was 0.99 (95% CI, 0.81 to 1.21). Polycythemia (hematocrit above 54%) occurred in 2.6% of testosterone-treated men versus 0.4% of placebo, confirming the need for hematocrit surveillance.

The FDA's 2015 labeling update requires all testosterone products to carry a warning about possible increased cardiovascular risk, though the TRAVERSE data have since provided reassurance for the transdermal route specifically. Oklahoma prescribers should discuss both the TRAVERSE findings and the FDA label language with patients before initiating therapy.

Skin transfer is another consideration. The AndroGel prescribing information warns that direct skin-to-skin contact with the application site can transfer testosterone to women and children, causing virilization. Patients should cover the site with clothing after the gel dries and wash hands immediately after application.